Comparative Pharmacology
Head-to-head clinical analysis: BLISOVI FE 1 20 versus NORMINEST FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLISOVI FE 1 20 versus NORMINEST FE.
BLISOVI FE 1/20 vs NORMINEST FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of ethinyl estradiol, an estrogen, and desogestrel, a progestin, which inhibit gonadotropin release (FSH and LH) from the pituitary, suppressing ovulation and altering cervical mucus and endometrial lining to reduce likelihood of fertilization and implantation.
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (FSH, LH). Increases cervical mucus viscosity, reducing sperm penetration. Norethindrone acetate is metabolized to norethindrone, which binds to progesterone receptors; ethinyl estradiol binds to estrogen receptors, providing contraceptive effect and cycle control.
One tablet orally once daily for 21 days, followed by 7 days of placebo (iron-containing) tablets. Each active tablet contains 0.1 mg levonorgestrel and 20 mcg ethinyl estradiol.
1 tablet orally once daily, starting on day 1 of menstrual cycle; each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg (21 active tablets) followed by 7 ferrous fumarate tablets.
None Documented
None Documented
Ethinyl estradiol: ~12-14 hours; norethindrone: ~7-8 hours; both allow once-daily dosing with steady-state reached within 7-10 days.
Norethindrone: 7-8 hours; ethinyl estradiol: 13-14 hours. Clinical context: steady-state in 5-7 days.
Renal: ~50-60% as metabolites; fecal: ~40-50% via biliary elimination; less than 10% unchanged in urine.
Renal 60-80% as metabolites, fecal 20-30% via bile, unchanged drug <5%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive